Résumé
Objective To assess the safety and efficacy of intravenous umbilical cord blood mononuclear cells in treatment of end stage heart failure (HF).Methods Twenty-one end stage HF patients with cardiac function Ⅳaccording to NYHA were treated with intravenous umbilical cord blood mononuclear cells.Their cardiac function was assessed,their NT-proBNP,LVEF,LVEDD were measured before and after treatment for 1 month,3 months and 6 months.Results Umbilical cord blood mononuclear cells were effective for 20 patients and ineffective for 1 patient who died within 30 days after treatment.The rate of improved cardiac function Ⅱ and Ⅲ was significantly higher while the serum NT-proBNP level was significantly lower after treatment for 1 month and 3 months (90.5％,95.2％ vs 0％,P＜0.05;3045.3±103.8 ng/L,3367.5±111.4 ng/L vs 5312.1±121.9 ng/L,P＜0.05).Conclusion Intravenous umbilical cord blood mononuclear cells are safe for end stage HF patients,alleviate their symptoms,improve their cardiac function and quality of life with no significant side effect.